Welcome to our dedicated page for Abcellera Biologics news (Ticker: ABCL), a resource for investors and traders seeking the latest updates and insights on Abcellera Biologics stock.
AbCellera Biologics Inc. (ABCL) is a leader in antibody discovery, combining microfluidics and advanced data science to accelerate therapeutic development. This page consolidates all official announcements and analysis-worthy updates about the company's progress in biopharmaceutical innovation.
Investors and industry observers will find timely updates on clinical milestones, financial performance, and strategic collaborations. Our curated feed includes earnings reports, partnership announcements with pharmaceutical entities, regulatory developments, and technological advancements in ABCL's antibody screening platform.
The resource prioritizes clarity and accessibility, offering both high-level summaries for casual observers and detailed technical updates for research-focused professionals. Content types include quarterly financial disclosures, intellectual property updates, executive leadership changes, and progress reports on therapeutic candidates in development.
Bookmark this page for streamlined tracking of ABCL's contributions to oncology, infectious disease treatment, and autoimmune disorder research. Check regularly for verified updates on how the company's proprietary discovery platform continues reshaping biotherapeutic development timelines.
AbCellera (Nasdaq: ABCL) has expanded its collaboration with Eli Lilly to develop antibody medicines for immunology, cardiovascular disease, and neuroscience programs. This builds on their successful partnership from March 2020, which included eight de novo programs and led to emergency use authorization for two COVID-19 antibody therapies. Under the new agreement, Lilly gains rights to develop and commercialize resulting therapeutic antibodies, while AbCellera receives an upfront payment, research payments, and potential milestone payments and royalties.
AbCellera's CEO, Carl Hansen, expressed excitement about deepening their partnership with Lilly, aiming to increase their impact on patients across multiple therapeutic areas. The expansion demonstrates the success of their initial collaboration and AbCellera's capabilities in antibody discovery and development.
AbCellera (Nasdaq: ABCL) will unveil its second quarter 2024 financial results on August 6, 2024. The company has scheduled an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. Interested parties can access the live audio webcast via a link on AbCellera's Investor Relations website, where a replay will also be available post-conference.
AbCellera (Nasdaq: ABCL) announced today that its executives will present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024, at 12:20 p.m. PT (3:20 p.m. ET). The presentation will be available via a live audio webcast on AbCellera's Investor Relations website, with a replay accessible afterward.
AbCellera reported Q1 2024 financial results with total revenue of $10.0 million and a net loss of $40.6 million. The company announced new collaborations, presented TCE program data at a cancer research meeting, and initiated partner programs. Key metrics show growth in partner programs and molecules in the clinic. Despite a decrease in revenue, AbCellera maintains strong liquidity of nearly $1 billion.
AbCellera, Viking Global Investors, and ArrowMark Partners have collaborated to launch new biotech companies focusing on advancing antibody drug programs. The partnership aims to create assets in the area of immunology, with Viking and ArrowMark overseeing program selection and funding, while AbCellera leverages its expertise in discovering and developing antibody medicines. Successful programs will lead to the creation of new companies, with AbCellera participating as an equity founding partner.
FAQ
What is the current stock price of Abcellera Biologics (ABCL)?
What is the market cap of Abcellera Biologics (ABCL)?
